圣诺生物：维培那肽原料药获上市批准

Core Viewpoint - The approval of the raw material drug Weipinatin by the National Medical Products Administration represents a significant achievement for the company, showcasing its comprehensive strengths in research, production, and quality management systems [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has received the approval notice for the marketing application of Weipinatin raw material drug [1] - Weipinatin is a polyethylene glycol-conjugated exenatide that acts as a GLP-1 receptor agonist, mimicking the physiological effects of natural human GLP-1 [1] Group 2: Therapeutic Use - The drug is designed to enhance insulin secretion in a glucose-dependent manner, thereby lowering blood sugar levels, which is beneficial for the treatment of type 2 diabetes and obesity [1] Group 3: Strategic Implications - The approval is expected to accumulate valuable experience for the company's future drug research and development, positively impacting its operational growth [1]